| 引用本文: | 张娜敏,陈方,黄艳玲,杨嘉永.基于Markov模型的丁苯酞序贯治疗再灌注后缺血性脑卒中成本-效用分析[J].中国现代应用药学,2025,42(4):70-75. |
| zhangnamin,Chenfang,Huang yan ling,Yang jiayong.Cost-Effectiveness of Sequential Therapy with Butylphthalide in Treatment of Ischemic Stroke after Reperfusion based on Markov Model[J].Chin J Mod Appl Pharm(中国现代应用药学),2025,42(4):70-75. |
|
| 摘要: |
| 目的 评价丁苯酞序贯治疗再灌注后急性缺血性脑卒中的经济性。方法 从中国卫生体系角度出发，基于1项随机对照临床试验研究结果，构建Markov模型，模拟无显著残疾、显著残疾、复发及死亡的动态变化。试验组为再灌注联合丁苯酞序贯治疗，对照组为再灌注联合安慰剂治疗。运用TreeAge Pro 2020软件构建药物经济学模型并模拟分析。结果 模型模拟30周期后，试验组的成本和产出分别为294039.09元和4.86质量调整生命年（QALYs）；对照组的成本和产出分别为269042.84元和4.66 QALYs。相比对照组，试验组的增量成本-效用为126816.55元/QALY，小于意愿支付意愿阈值。敏感性分析结果显示该经济学评价结果稳定。结论 对于血管再通的急性缺血性脑卒中患者而言，相比于安慰剂，丁苯酞序贯治疗为具有成本-效用的方案。 |
| 关键词: 丁苯酞 缺血性脑卒中 Markov模型 成本-效用分析 药物经济学评价 |
| DOI： |
| 分类号:R956 |
| 基金项目: |
|
| Cost-Effectiveness of Sequential Therapy with Butylphthalide in Treatment of Ischemic Stroke after Reperfusion based on Markov Model |
|
zhangnamin1, Chenfang2, Huang yan ling1, Yang jiayong2
|
|
1.The School of Pharmacy, Fujian Medical University;2.Department of Pharmacy, the First Affiliated Hospital of Xiamen University
|
| Abstract: |
| OBJECTIVE To evaluate the economic of sequential therapy with butylphthalide for patients with cerebral acute ischemic stroke. METHODS From the perspective of the health system, based on the results of a randomized controlled clinical trial, a long-term Markov model was constructed to simulate the dynamic changes of no significant disability, significant disability, recurrence, and death. The experimental group was treated with reperfusion combined with sequential butylphthalide, while the control group was treated with reperfusion combined with placebo. The cost-utility and sensitivity analysis were performed for two regimens by TreeAge Pro 2020. RESULTS After 30 cycles of model simulation, results showed that the cost and output of the experimental group were 294039.09 yuan and 4.86 quality adjusted life years (QALYs); results showed that the cost and output of the control group were 269042.84 yuan and 4.66 QALYs. Compared with the control group, the incremental cost effectiveness of the experimental group was 126816.55 yuan/ QALY, which is less than the willingness to pay threshold. The sensitivity analysis supported the robustness of the results. CONCLUSION For acute ischemic stroke patients with vascular recanalization, compared to placebo, sequential treatment with butylphthalide is a pharmacoeconomic advantageous treatment. |
| Key words: butylphthalide cerebral ischemic stroke Markov model cost-utility analysis pharmacoeconomic evaluation |
